Contineum Therapeutics, Inc. Payments to Acquire Marketable Securities
Contineum Therapeutics, Inc. (CTNM) reported Payments to Acquire Marketable Securities of $142.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-30
- Contineum Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $45.78M, a 79.99% increase year-over-year.
- Contineum Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $97.12M, a 188.26% increase year-over-year.
- Contineum Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $84.73M, a 55.89% increase year-over-year.
- Contineum Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $18.64M, a 74.25% decline year-over-year.
- Contineum Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $162.50M, a 28.23% decline from fiscal 2024.
- Contineum Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $226.41M, a 59.59% increase from fiscal 2023.
- Contineum Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $141.87M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $142.90M 10-Q · filed 2026-07-30 | $227.63M derived: sum of 3 quarters · filed 2026-07-30 | $246.28M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $97.12M 10-Q · filed 2026-05-05 | $181.85M derived: sum of 2 quarters · filed 2026-05-05 | $200.49M derived: sum of 3 quarters · filed 2026-05-05 | $225.93M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $84.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $103.37M derived: sum of 2 quarters · filed 2026-03-05 | $128.81M derived: sum of 3 quarters · filed 2026-07-30 | $162.50M 10-K · filed 2026-03-05 |
| 2025-09-30 | $18.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $44.08M derived: sum of 2 quarters · filed 2026-07-30 | $77.77M 10-Q · filed 2025-10-30 | $132.12M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $25.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $59.13M 10-Q · filed 2026-07-30 | $113.48M derived: sum of 3 quarters · filed 2026-07-30 | $185.89M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $33.69M 10-Q · filed 2026-05-05 | $88.04M derived: sum of 2 quarters · filed 2026-05-05 | $160.45M derived: sum of 3 quarters · filed 2026-05-05 | $229.46M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $54.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $126.76M derived: sum of 2 quarters · filed 2026-03-05 | $195.77M derived: sum of 3 quarters · filed 2026-03-05 | $226.41M 10-K · filed 2026-03-05 |
| 2024-09-30 | $72.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $141.41M derived: sum of 2 quarters · filed 2025-10-30 | $172.05M 10-Q · filed 2025-10-30 | $194.05M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $69.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $99.65M 10-Q · filed 2025-08-05 | $121.64M derived: sum of 3 quarters · filed 2025-08-05 | $173.72M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $30.64M 10-Q · filed 2025-05-14 | $52.64M derived: sum of 2 quarters · filed 2025-05-14 | $104.71M derived: sum of 3 quarters · filed 2025-05-14 | $163.29M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $74.07M derived: sum of 2 quarters · filed 2025-03-06 | $132.65M derived: sum of 3 quarters · filed 2025-03-06 | $141.87M 10-K · filed 2025-03-06 |
| 2023-09-30 | $52.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $110.65M derived: sum of 2 quarters · filed 2024-11-06 | $119.87M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $58.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $67.79M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $9.22M 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |